Why Pfizer Is a Turnaround Play Worth Watching in 2026

In this episode of Stock Picking with Fexingo, Lucas and Luna dig into the case for Pfizer as a potential turnaround stock in mid-2026. With shares trading around $25, down from pandemic highs, they discuss the company's pipeline catalysts, cost-cutting efforts, and the role of its dividend in a volatile market. Lucas explains why the market's pessimism might be overdone, while Luna pushes back on the risk of patent cliffs and lack of blockbuster growth. They reference the Russell 2000's recent weakness and value stock outperformance to frame the broader backdrop. A focused look at one of the most debated names in large-cap pharma, and whether it belongs in a concentrated portfolio. #Pfizer #TurnaroundStock #Pharma #Dividend #StockPicking #ValueInvesting #Contrarian #Pipeline #PatentCliff #LargeCap #Healthcare #Biotech #Investing #FexingoBusiness #BusinessPodcast #Finance #June2026 #ConcentratedPortfolio Keep every episode free: buymeacoffee.com/fexingo